Pfizer (PFE) Share-based Compensation (2009 - 2026)

Pfizer (PFE) has 18 years of Share-based Compensation data on file, last reported at $272.0 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $272.0 million, up 60.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $901.0 million (down 30.48% YoY), and the FY2025 annual result was $799.0 million, down 8.89% from the prior year.
• Share-based Compensation advanced to $272.0 million in Q1 2026 per PFE's latest filing, from $225.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $700.0 million in Q3 2024 and troughed at $86.0 million in Q2 2022.
• A 5-year average of $240.2 million and a median of $203.0 million in 2025 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation soared 363.58% in 2024, then slumped 71.29% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $508.0 million in 2022, then sank by 76.18% to $121.0 million in 2023, then surged by 478.51% to $700.0 million in 2024, then tumbled by 67.86% to $225.0 million in 2025, then rose by 20.89% to $272.0 million in 2026.
• Business Quant data shows PFE's Share-based Compensation at $272.0 million in Q1 2026, $225.0 million in Q4 2025, and $201.0 million in Q3 2025.